We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
+14.14%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$94.3B
AUM Growth
+$7.96B
(+9.2%)
Cap. Flow
-$2.37B
Cap. Flow
% of AUM
-2.52%
Top 10 Holdings %
Top 10 Hldgs %
12.56%
Holding
2,315
New
140
Increased
934
Reduced
1,002
Closed
155
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$335M |
| 2 |
Exelon
EXC
|
+$314M |
| 3 |
Procter & Gamble
PG
|
+$241M |
| 4 |
TripAdvisor
TRIP
|
+$208M |
| 5 |
Starbucks
SBUX
|
+$182M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Walmart Inc
WMT
|
+$551M |
| 2 |
Target
TGT
|
+$514M |
| 3 |
CELG
Celgene Corp
CELG
|
+$495M |
| 4 |
Cigna
CI
|
+$369M |
| 5 |
Costco
COST
|
+$310M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.77% |
| 2 | Healthcare | 19.09% |
| 3 | Consumer Discretionary | 13.69% |
| 4 | Industrials | 9.28% |
| 5 | Financials | 9.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1926
Simmons First National
SFNC
$3.39B
| $345K | ﹤0.01% |
14,079
+418
| +3% | +$10.7K |
|
|
AVNS
1927
DELISTED
Avanos Medical
AVNS
| $344K | ﹤0.01% |
8,126
-5,738
| -41% | -$257K |
|
1928
Gentherm
THRM
$1.27B
| $342K | ﹤0.01% |
9,273
+469
| +5% | +$19.1K |
|
1929
Evolent Health
EVH
$447M
| $339K | ﹤0.01% |
26,923
+427
| +2% | +$6.76K |
|
1930
Preferred Bank
PFBC
$1.25B
| $339K | ﹤0.01% |
7,541
-2,530
| -25% | -$120K |
|
1931
Western Union
WU
$2.21B
| $337K | ﹤0.01% |
18,264
-1,583
| -8% | -$28.5K |
|
1932
Avis
CAR
$5.02B
| $336K | ﹤0.01% |
9,645
+515
| +6% | +$15.4K |
|
1933
Kadant
KAI
$3.99B
| $336K | ﹤0.01% |
3,824
-13,361
| -78% | -$1.15M |
|
1934
Thor Industries
THO
$4.14B
| $335K | ﹤0.01% |
5,376
-202
| -4% | -$12.8K |
|
1935
Astronics
ATRO
$3.84B
| $333K | ﹤0.01% |
12,212
+2,008
| +20% | +$53.5K |
|
1936
Gibraltar Industries
ROCK
$1.49B
| $333K | ﹤0.01% |
8,205
+19
| +0.2% | +$725 |
|
1937
Smart Sand
SND
$194M
| $332K | ﹤0.01% |
74,530
-6,440
| -8% | -$19.5K |
|
1938
Vanda Pharmaceuticals
VNDA
$302M
| $330K | ﹤0.01% |
17,911
+3,916
| +28% | +$89.2K |
|
1939
BOK Financial
BOKF
$8.74B
| $329K | ﹤0.01% |
4,029
-19,196
| -83% | -$1.61M |
|
|
CPE
1940
DELISTED
Callon Petroleum Company
CPE
| $329K | ﹤0.01% |
4,352
-33,134
| -88% | -$2.57M |
|
1941
Marvell Technology
MRVL
$196B
| $328K | ﹤0.01% |
16,602
-60,215
| -78% | -$1.13M |
|
|
VIA
1942
DELISTED
Via Renewables, Inc. Class A Common Stock
VIA
| $328K | ﹤0.01% |
7,360
| – | – |
|
1943
Viking Therapeutics
VKTX
$4B
| $327K | ﹤0.01% |
32,900
-1,256
| -4% | -$10.5K |
|
|
VNTR
1944
DELISTED
Venator Materials PLC
VNTR
| $327K | ﹤0.01% |
58,195
+42,131
| +262% | +$224K |
|
1945
Harmonic Inc
HLIT
$1.28B
| $326K | ﹤0.01% |
60,063
+1,877
| +3% | +$9.95K |
|
|
KYNB
1946
Kyntra Bio
KYNB
$29.4M
| $325K | ﹤0.01% |
239
-80
| -25% | -$108K |
|
1947
Tucows
TCX
$175M
| $325K | ﹤0.01% |
3,998
-960
| -19% | -$69.9K |
|
1948
Heron Therapeutics
HRTX
$92.9M
| $323K | ﹤0.01% |
+13,202
| New | +$346K |
|
|
GTHX
1949
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $323K | ﹤0.01% |
19,447
-13,028
| -40% | -$247K |
|
|
CALA
1950
DELISTED
Calithera Biosciences, Inc
CALA
| $323K | ﹤0.01% |
2,396
-847
| -26% | -$89K |
|
Similar funds
VGA
AQR Capital Management's Q1 2019 Portfolio in Review
As of Q1 2019, AQR Capital Management held 2,315 positions worth $94.3B, up 9.2% from $86.3B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
AQR Capital Management's Q1 2019 filing shows 140 new, 934 increased, 1,002 reduced and 155 closed positions. Its largest new stake was Canopy Growth: 121,700 shares worth $52.7M. The largest sale was Walmart Inc, an estimated $551M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 18% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- AQR Capital Management's largest Q1 2019 buy was Canopy Growth: 121,700 shares worth $52.7M.
- AQR Capital Management added most to Biogen in Q1 2019, an estimated $335M increase.
- AQR Capital Management's biggest Q1 2019 reduction was Walmart Inc, cutting an estimated $551M.
- AQR Capital Management fully exited Dun & Bradstreet in Q1 2019, selling an estimated $74.4M.
- AQR Capital Management's ten largest holdings make up 13% of its $94.3B portfolio in Q1 2019.
- AQR Capital Management opened 140 new positions and closed 155 in Q1 2019.
- AQR Capital Management's portfolio value rose 9.2% quarter-over-quarter to $94.3B.
Based on AQR Capital Management's 13F filing for Q1 2019, filed 14 May 2019.